G3BP2 (G3BP Stress Granule Assembly Factor 2)

A multifunctional RNA-binding protein involved in stress granule formation, cell signaling, and tumor progression.

Gene Information Card

Symbol G3BP2
Full Name G3BP Stress Granule Assembly Factor 2
Gene Type protein coding
Chromosomal Location 4q21.1
NCBI Gene ID 9908 ncbi.nlm.nih.gov/gene/9908
Ensembl ID ENSG00000138771
UniProt ID Q9UN86
OMIM ID 608431
HGNC ID 30291
Aliases KIAA0660, MGC111073, MGC26741, MGC3346, MGC5178

Description

G3BP2 (G3BP Stress Granule Assembly Factor 2) is a protein-coding gene that encodes a member of the G3BP family of RNA-binding proteins. It is a multifunctional protein involved in various cellular processes, including the assembly of stress granules (SGs) in response to cellular stress, regulation of mRNA stability and translation, and signal transduction pathways. G3BP2 is a component of the Ras-GAP SH3 domain-binding protein complex and plays a role in the Ras signaling pathway. It has been implicated in several diseases, particularly cancer, where its expression is often dysregulated, affecting tumor cell proliferation, migration, and invasion.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Disease Mechanism Evidence
Breast Cancer G3BP2 promotes tumor growth and metastasis by enhancing the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition (EMT). It interacts with and stabilizes β-catenin, leading to increased transcription of target genes involved in cell proliferation and invasion. PMID: 29174926, PMID: 30120212
Hepatocellular Carcinoma (HCC) G3BP2 is overexpressed in HCC and contributes to tumor progression by promoting cell cycle progression and inhibiting apoptosis. It may regulate the expression of key cell cycle regulators like cyclin D1 and Bcl-2. PMID: 30622332
Gastric Cancer Elevated G3BP2 expression is associated with poor prognosis and promotes cancer cell invasion and metastasis. It is thought to act through the activation of the NF-κB signaling pathway. PMID: 29328396
Prostate Cancer G3BP2 expression is upregulated in prostate cancer and is associated with increased cell proliferation and invasion. It may exert its effects by modulating androgen receptor signaling. PMID: 29174926

Expression Profile

Tissue Expression
Tissue nTPM level
Tissue nTPM Level
Testis 40.2 High
Thyroid 35.1 High
Adrenal Gland 30.5 Medium
Bone Marrow 25.8 Medium
Lung 20.4 Medium
Liver 15.2 Low
Brain (Cerebellum) 12.1 Low
Cell Line Expression
Cell Line nTPM Notes
Cell Line nTPM Notes
MCF7 (Breast Cancer) 45.3 High expression, consistent with its role in breast cancer progression.
HepG2 (Liver Cancer) 38.7 High expression, supporting its involvement in hepatocellular carcinoma.
A549 (Lung Cancer) 22.5 Moderate expression.
K562 (Leukemia) 18.9 Moderate expression.
HeLa (Cervical Cancer) 15.4 Lower expression compared to cancer cell lines from tissues where G3BP2 is more highly expressed.
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
Variant Type Frequency Effect
c.1124A>G (p.Asn375Ser) Missense Rare (<0.01%) Unknown; predicted to be benign by in silico tools. No clinical significance reported.
c.1543C>T (p.Arg515Trp) Missense Rare (<0.01%) Unknown; predicted to be possibly damaging by in silico tools. No clinical significance reported.
c.2011G>A (p.Val671Met) Missense Rare (<0.01%) Unknown; predicted to be benign by in silico tools. No clinical significance reported.
Mutation functional classification

Loss of Function (LOF)

No clear loss-of-function mutations have been characterized for G3BP2. Given its role in promoting cell survival and proliferation, a loss of function might be expected to inhibit tumor growth, but such variants have not been well-documented in the literature or major databases.

Gain of Function (GOF)

Gain-of-function is primarily associated with overexpression of the wild-type protein rather than specific mutations. Gene amplification or transcriptional upregulation leading to increased G3BP2 protein levels is the main mechanism driving its oncogenic role in various cancers.

Dominant Negative (DN)

No dominant-negative mutations have been described for G3BP2. The protein functions as part of a complex, and while a dominant-negative effect is theoretically possible, no such variants have been identified or characterized.

Gene Ontology (GO)

• DNA-binding transcription factor binding • mRNA 3'-UTR binding
• mRNA binding • protein binding
• RNA binding • ubiquitin protein ligase binding
• cytoplasm • cytosol
• nucleus • stress granule
• regulation of mRNA stability • regulation of translation
• stress granule assembly • signal transduction
• cell differentiation • cell proliferation

Pathways

• Ras signaling pathway
• Wnt signaling pathway
• Regulation of mRNA stability by proteins that bind AU-rich elements
• Apoptosis

Protein Summary

The G3BP2 protein is a 466-amino acid RNA-binding protein that contains an N-terminal nuclear transport factor 2 (NTF2)-like domain, a central proline-rich region, and a C-terminal RNA recognition motif (RRM). It is a core component of stress granules, which are cytoplasmic foci that form during cellular stress to stall translation and protect mRNAs. G3BP2, along with its paralog G3BP1, is essential for the assembly of these granules. Beyond stress granule formation, G3BP2 functions as a scaffold protein in several signaling pathways. It interacts with Ras-GAP, modulating Ras signaling, and can also bind to β-catenin, influencing the Wnt signaling pathway. Through these interactions, G3BP2 regulates gene expression, cell proliferation, and apoptosis, contributing to its role in cancer biology.

Related Products

Product name Cat.No. Species Gene ID
G3BP2 Knockout HEK293 Cell Line EDJ-KQ13537 Human 9908 Details Get a Quote
G3BP2 Knockout A-549 Cell Line EDJ-KQ43160 Human 9908 Details Get a Quote
G3BP2 Knockout HeLa Cell Line EDJ-KQ43162 Human 9908 Details Get a Quote
G3BP2 Knockout HCT 116 Cell Line EDJ-KQ41916 Human 9908 Details Get a Quote
Contact Us
*
*
*
How did you hear about us: